Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Metastatic Breast Cancer Therapy Effectiveness Gauged By Immunicon Kits

This article was originally published in The Gray Sheet

Executive Summary

Veridex is rolling out Immunicon's circulating tumor cell selection and enumeration IVD systems to roughly 20 U.S. comprehensive cancer centers and clinical labs

You may also be interested in...

CellSearch study

Counting circulating tumor cells with J&J/Veridex's cancer diagnostic system before treatment can independently predict progression-free survival and overall survival rates in patients with metastatic breast cancer, according to a 177-patient trial led by Massimo Cristofanilli, MD, University of Texas, published in the Aug. 19 NEJM. The CellSearch system was 510(k) cleared in June and likely will be commercially available this fall, according to Veridex...

Immunicon IPO Proceeds To Support FDA Clearance Of Cancer Diagnostics

Johnson & Johnson/Veridex will stand to benefit from Immunicon's proposed $70.9 mil. IPO under the terms of the companies' exclusive development, licensing and marketing agreement for cancer diagnostics

Merz Consumer Care Optimistic About Future As German Lockdown Continues

Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure. 




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts